<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370691</url>
  </required_header>
  <id_info>
    <org_study_id>Rev: 03 September 2019</org_study_id>
    <nct_id>NCT04370691</nct_id>
  </id_info>
  <brief_title>JET Enhanced Thrombectomy Intervention</brief_title>
  <acronym>JETi</acronym>
  <official_title>JET Enhanced Thrombectomy Intervention - JETi Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walk Vascular LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walk Vascular LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate real world patient outcomes after treatment of acute and non-acute upper and lower
      extremity venous and arterial thrombosis with the JETi Thrombectomy System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The JETi Registry is an open label, prospective, non-randomized, multi-center observational
      registry including 250 patients who meet eligibility from up to 30 sites worldwide. Patient
      participation will be 12 months including post procedure follow-up contact at 10 days, 3, 6
      and 12 months. The study duration is estimated at 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Change in Percent of Occlusion From Baseline to Final Angiogram/Venogram</measure>
    <time_frame>0 days</time_frame>
    <description>From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms/venograms, each vessel will be assigned a value by the independent core lab.
Complete occlusion (&gt;90% occlusion)
Substantial occlusion (50-90% occlusion OR &lt;50% occlusion and &gt;3cm in length)
Partial occlusion (&lt;50% occlusion AND &lt;3cm in length)
Patent/Normal (without visible thrombus or occlusion)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rethrombosis</measure>
    <time_frame>up to 12 Month Follow Up</time_frame>
    <description>The number of patients affected by rethrombosis of the treated vessels (first episode) throughout a 12 Month Follow-Up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>0 days</time_frame>
    <description>Change in the degree of occlusion from baseline to final angiogram</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Peripheral Artery Thrombosis</condition>
  <condition>Embolism</condition>
  <condition>Limb Ischemia</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Hemodialysis Access Thrombosis</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Deep Vein Thrombosis</arm_group_label>
    <description>Patients presenting with deep vein thrombosis for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Limb Ischemia</arm_group_label>
    <description>Patients presenting with limb ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis Access</arm_group_label>
    <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Thrombotic Conditions</arm_group_label>
    <description>Patients presenting with a thrombotic condition other than deep vein thrombosis, limb ischemia or thrombosed hemodialysis access for treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JETi Thrombectomy System</intervention_name>
    <description>Thrombectomy</description>
    <arm_group_label>Deep Vein Thrombosis</arm_group_label>
    <arm_group_label>Hemodialysis Access</arm_group_label>
    <arm_group_label>Limb Ischemia</arm_group_label>
    <arm_group_label>Other Thrombotic Conditions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community Population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been treated for acute/sub-acute thrombosis in the peripheral vascular
             system with any of the JETi® Peripheral Thrombectomy System Catheters

          -  Patient has provided appropriate consent/authorization per the site's institutional
             policy and procedure.

          -  Age ≥ 18 years.

        Exclusion Criteria:

          -  Patient has previously been enrolled in JETi Registry in the last 12 months.

          -  Current participation in another drug or device trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

